Phathom - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים PHAT

The success of Phathom Pharmaceuticals (PHAT) relies on the rollout pace of ulcer medications and insurance coverage recognition in the US. Patent protection of formulas and certification complexities create a temporary brand monopoly. Growth is driven by the expansion of Voquezna within the multi-billion dollar GERD market. Year-over-year (TTM) operating revenue dynamics confirm this trend, where the 87.40 mark serves as a key metric for the current state of the business.
Phathom Pharmaceuticals, Inc. - פילוחים אנליטיים ומדדי מפתח (PHAT)

Trailing twelve-month revenue dynamics measure the pace of business expansion by comparing current income with the same period last year to identify operational resilience trends. Analysis of this TTM annual sales growth chart confirms the effective commercial rollout of the primary drug from Phathom Pharmaceuticals (PHAT), reflecting growing loyalty within the medical community and the strengthening of the brand's market position.